跳至主要内容
临床试验/NCT02417818
NCT02417818已完成不适用

Effects of Plasma Therapy in Cutaneous Microcirculation of Different Wounds

University Hospital Schleswig-Holstein1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2015年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
240
试验地点
1
主要终点
Change in microcirculation (composite measure)

研究概览

简要总结

In plastic and reconstructive surgery, treatment strategies of second-degree burns, superficial wounds, burn scars, flaps and chronic wounds aim at reducing infection and improving microcirculation. Although previous studies indicate that Plasma Therapy can accelerate wound healing, only a few studies focused on the elucidation of its mechanisms of action. Therefore, the aim of this study is to evaluate the microcirculatory effects of Plasma Therapy on second-degree burns, superficial wounds, burn scars, flaps and chronic wounds in a human in-vivo setting for the first time.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
  • •Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
  • •Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
  • •Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident. No soft tissue injury must be evident.
  • •Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
  • •Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
  • •Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
  • •Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups E-G must be evident. No soft tissue injury must be evident.
  • •Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn wound.
  • •Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn wound.
  • •Group K (n=20): Consent-capable male and female patients ≥18 years of age received a flap.
  • •Group L (n=20): Consent-capable male and female patients ≥18 years of age received a flap.

排除标准

  • •General exclusion criteria
  • •below 18 years of age
  • •wounds requiring artificial respiration, since consent for the study participation is unobtainable
  • •Exclusion criteria groups A, B, D, E, F, H:
  • •peripheral arterial occlusive disease
  • •vasculitis
  • •diabetes mellitus
  • •chronic kidney or liver disease
  • •cardiac dysfunction
  • •arterial hypo- or hypertension
  • •Anamnestic exclusion criteria
  • •ongoing immunosuppressive or chemotherapy treatment
  • •drug abuse
  • •systemic skin diseases
  • •systemic and local cortisone therapy

研究组 & 干预措施

Second-Degree Burn

Experimental

Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.

Intervention: Plasma Therapy (PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Skin Excision (for Skin Graft)

Experimental

Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.

Intervention: Plasma Therapy (PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Chronic Wound

Experimental

Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.

Intervention: Plasma Therapy (PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Intact Skin

Active Comparator

Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.

Intervention: Plasma Therapy (PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Second-Degree Burn (repetitive)

Experimental

Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

Skin Excision (for Skin Graft) (repetitive)

Experimental

Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

Chronic Wound (repetitive)

Experimental

Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

Intact Skin (repetitive)

Active Comparator

Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

Hypertrophic burn scar

Experimental

Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Hypertrophic burn scar (repetitive)

Experimental

Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

Flap

Experimental

Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Plasma Therapy (PlasmaDerm) (Device)

Flap (repetitive)

Experimental

Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.

Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)

干预措施: Repetitive Plasma Therapy (repetitive PlasmaDerm) (Device)

结局指标

主要结局

Change in microcirculation (composite measure)

时间窗: Baseline and 1 minute post-dose

* capillary blood flow \[arbitrary units AU\] * capillary blood velocity \[AU\] * tissue oxygen saturation \[%\] * relative postcapillary venous filling pressure \[AU\]

次要结局

  • Change in microcirculation (areolar measure)(Baseline, while and 1 minute post-dose)

研究者

发起方
University Hospital Schleswig-Holstein
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tobias Kisch

MD

University Hospital Schleswig-Holstein

研究点 (1)

Loading locations...

相似试验